Advanced Kidney Cancer - Pipeline Insight, 2025
Description
DelveInsight’s, “Advanced Kidney Cancer - Pipeline Insight, 2025” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Advanced Kidney Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Advanced Kidney Cancer: Overview
Advanced Kidney Cancer (also known as advanced renal cell carcinoma) is the most common type of cancer arising in the kidney, making up more than 9 out of 10 renal cancers in adults. Other types include transitional cell carcinomas of the renal pelvis, which behave like bladder cancers. Renal sarcoma is another rare tumor of the kidney. Cigarette and cigar smoking are the strongest risk factors for renal cell carcinoma (RCC), with obesity, especially in women, being another major risk factor. Eliminating tobacco smoking and excess body weight could potentially halve the incidence of kidney cancers. Other contributing risk factors include high blood pressure, chronic renal failure, and occupational exposure to certain chemicals. Moderate alcohol consumption, a diet rich in fruits and vegetables, and long-term fatty fish consumption are associated with reduced RCC risk. Mutations in the VHL gene are implicated in the development of both sporadic and familial clear cell RCC, while the MET gene is a feature of the familial type of papillary RCC.
Prescribing systemic therapy for advanced or metastatic RCC requires oncology specialists knowledgeable about the disease, drug, toxicities, interactions, and treatment monitoring. Patients benefit from a multidisciplinary approach with nursing, dietary, and pharmacy support for optimal management. Regular patient evaluations are crucial to identify and manage toxicities effectively, ensuring patient safety and treatment efficacy. Providing comprehensive information on potential side effects, prevention, and management to patients and caregivers is essential for informed decision-making and care.
Accurate staging is crucial for the effective management of renal cell carcinoma (RCC), with stage-dependent therapeutic options. In Stage 1a, tumors confined to the kidney are treated with curative intent through complete surgical resection, preferably with nephron-sparing partial nephrectomy. Surveillance includes abdominal CT or MRI within six months of initiation and annual imaging thereafter. For Stage 1b, partial or radical nephrectomy is recommended, with follow-up imaging schedules varying post-surgery. Stages 2 and 3 typically involve radical nephrectomy, with specific follow-up imaging protocols. In Stage 4, systemic targeted molecular therapies like VEGF-TKIs or rapamycin inhibitors are preferred over immunotherapy, with nephrectomy followed by immunotherapy showing improved survival. Follow-up includes pretreatment imaging and regular monitoring every 6 to 16 weeks based on clinical status.
""Advanced Kidney Cancer- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Kidney Cancer pipeline landscape is provided which includes the disease overview and Advanced Kidney Cancer treatment guidelines. The assessment part of the report embraces, in depth Advanced Kidney Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Kidney Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Advanced Kidney Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Advanced Kidney Cancer Emerging Drugs
Savolitinib: AstraZeneca
Savolitinib is an oral, potent, and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations or gene amplification. The drug is currently being evaluated under Phase III clinical trial for the treatment of advanced kidney cancer.
Relatlimab: Bristol-Myers Squibb
Relatlimab is a lymphocyte activation gene-3 (LAG-3) blocking antibody and is expressed in a recombinant CHO cell line. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with advanced kidney cancer.
Further product details are provided in the report……..
Advanced Kidney Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Advanced Kidney Cancer drugs segregated based on following parameters that define the scope of the report, such as:
Advanced Kidney Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Kidney Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Kidney Cancer drugs.
Advanced Kidney Cancer Report Insights
Current Treatment Scenario and Emerging Therapies:
Please Note: It will take 5-6 business days to complete the report upon order confirmation.
Geography Covered
- Global coverage
Advanced Kidney Cancer: Overview
Advanced Kidney Cancer (also known as advanced renal cell carcinoma) is the most common type of cancer arising in the kidney, making up more than 9 out of 10 renal cancers in adults. Other types include transitional cell carcinomas of the renal pelvis, which behave like bladder cancers. Renal sarcoma is another rare tumor of the kidney. Cigarette and cigar smoking are the strongest risk factors for renal cell carcinoma (RCC), with obesity, especially in women, being another major risk factor. Eliminating tobacco smoking and excess body weight could potentially halve the incidence of kidney cancers. Other contributing risk factors include high blood pressure, chronic renal failure, and occupational exposure to certain chemicals. Moderate alcohol consumption, a diet rich in fruits and vegetables, and long-term fatty fish consumption are associated with reduced RCC risk. Mutations in the VHL gene are implicated in the development of both sporadic and familial clear cell RCC, while the MET gene is a feature of the familial type of papillary RCC.
Prescribing systemic therapy for advanced or metastatic RCC requires oncology specialists knowledgeable about the disease, drug, toxicities, interactions, and treatment monitoring. Patients benefit from a multidisciplinary approach with nursing, dietary, and pharmacy support for optimal management. Regular patient evaluations are crucial to identify and manage toxicities effectively, ensuring patient safety and treatment efficacy. Providing comprehensive information on potential side effects, prevention, and management to patients and caregivers is essential for informed decision-making and care.
Accurate staging is crucial for the effective management of renal cell carcinoma (RCC), with stage-dependent therapeutic options. In Stage 1a, tumors confined to the kidney are treated with curative intent through complete surgical resection, preferably with nephron-sparing partial nephrectomy. Surveillance includes abdominal CT or MRI within six months of initiation and annual imaging thereafter. For Stage 1b, partial or radical nephrectomy is recommended, with follow-up imaging schedules varying post-surgery. Stages 2 and 3 typically involve radical nephrectomy, with specific follow-up imaging protocols. In Stage 4, systemic targeted molecular therapies like VEGF-TKIs or rapamycin inhibitors are preferred over immunotherapy, with nephrectomy followed by immunotherapy showing improved survival. Follow-up includes pretreatment imaging and regular monitoring every 6 to 16 weeks based on clinical status.
""Advanced Kidney Cancer- Pipeline Insight, 2025"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Advanced Kidney Cancer pipeline landscape is provided which includes the disease overview and Advanced Kidney Cancer treatment guidelines. The assessment part of the report embraces, in depth Advanced Kidney Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Advanced Kidney Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Kidney Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Advanced Kidney Cancer.
This segment of the Advanced Kidney Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II/III, II, I, preclinical and discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Advanced Kidney Cancer Emerging Drugs
Savolitinib: AstraZeneca
Savolitinib is an oral, potent, and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations or gene amplification. The drug is currently being evaluated under Phase III clinical trial for the treatment of advanced kidney cancer.
Relatlimab: Bristol-Myers Squibb
Relatlimab is a lymphocyte activation gene-3 (LAG-3) blocking antibody and is expressed in a recombinant CHO cell line. The drug is currently being evaluated under Phase II clinical trial for the treatment of patients with advanced kidney cancer.
- JANX008: Janux Therapeutics
Further product details are provided in the report……..
Advanced Kidney Cancer: Therapeutic Assessment
This segment of the report provides insights about the different Advanced Kidney Cancer drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Advanced Kidney Cancer
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
- Molecule Type
- Monoclonal antibody
- Small molecule
- Peptide
- Product Type
Advanced Kidney Cancer: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Advanced Kidney Cancer therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Advanced Kidney Cancer drugs.
Advanced Kidney Cancer Report Insights
- Advanced Kidney Cancer Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Advanced Kidney Cancer drugs?
- How many Advanced Kidney Cancer drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Advanced Kidney Cancer?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Advanced Kidney Cancer therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Advanced Kidney Cancer and their status?
- What are the key designations that have been granted to the emerging drugs?
- Janux Therapeutics
- Infinity Pharmaceuticals
- Merck Sharp & Dohme
- Xencor
- Exelixis
- X4 Pharmaceuticals
- Nykode Therapeutics
- Tarus Therapeutics
- AstraZeneca
- RemeGen
- NiKang Therapeutics
- NGM Biopharmaceuticals
- MedImmune
- JANX008
- IPI-549
- Belzutifan
- XmAb 808
- XL092
- X4P-001
- VB10.NEO
- TT-10
- Savolitinib
- RC198
- NKT2152
- NGM707
- MEDI5752
Please Note: It will take 5-6 business days to complete the report upon order confirmation.
Table of Contents
180 Pages
- Introduction
- Executive Summary
- Advanced Kidney Cancer: Overview
- Definition
- Causes
- Signs and Symptoms
- Etiology
- Treatment/Management of Advanced Kidney Cancer
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Advanced Kidney Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Savolitinib: AstraZeneca
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- Relatlimab: Bristol-Myers Squibb
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- JANX008: Janux Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- Comparative Analysis
- Drug name: Company name
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Advanced Kidney Cancer Key Companies
- Advanced Kidney Cancer Key Products
- Advanced Kidney Cancer- Unmet Needs
- Advanced Kidney Cancer- Market Drivers and Barriers
- Advanced Kidney Cancer- Future Perspectives and Conclusion
- Advanced Kidney Cancer Analyst Views
- Advanced Kidney Cancer Key Companies
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
